Carfilzomib is used to treat patients with relapsed or refractory multiple myeloma who have received one to three previous treatments for multiple myeloma.
Please fill in the details about your medicine requirement on this form.
60/4, T&T House. Yusuf Sarai.
New Delhi:110016 India.
Carfilzomib (marketed under the trade name Kyprolis, developed by Onyx Pharmaceuticals) is an anti-cancer drug acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin. The U.S. Food and Drug Administration (FDA) approved it on 20 July 2012 for use in patients with multiple myeloma who have received at least two prior therapies, including treatment with bortezomib and an immunomodulatory therapy (such as lenalidomide) and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Global Pharma Network can help you to provide access of Carfilzomib medications sold under the brand name for Multiple Myeloma treatment by connecting Patients, Health Care Centers, Pharmacies and Retail Outlets with approved supplier, exporter and distributor of Generic drugs, innovator brands and biosimilar medicines from India. Call Mr. Tarun at +91 8744044044 for more details.
The Global Pharma Network is not an online pharmacy company but we help patient to connect with suppliers in the delivering of Multiple Myeloma medications a pharmaceutical drug (prescription drug, prescription medication or prescription medicine) that legally requires a medical prescription to be dispensed in following countries as per the customer's prescribed medication and applicable regulatory approval.
US FDA Trade Name Available: Kyprolis. Indian Manaufacturer Brands Available:
Global Pharma Network will help you in importing and exporting this medicine only upon the valid prescription of a licensed medical practitioner and other documents as required by the laws of the jurisdiction in which you are present. USA, UK, Russia, China, India, Nepal, Bhutan, Myanmar / Burma, Laos, Thailand, Cambodia, Hong Kong, Macau, Malaysia, Indonesia, Middle East, Japan, Philippines.